Q2 EPS Forecast for United Therapeutics Boosted by Analyst

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for United Therapeutics in a report released on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $8.08 per share for the quarter, up from their prior estimate of $7.20. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q4 2025 earnings at $6.75 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.17 EPS.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Cantor Fitzgerald started coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. Finally, Morgan Stanley raised their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $393.00.

United Therapeutics Stock Up 1.9%

Shares of UTHR stock opened at $325.82 on Monday. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $417.82. The business's 50 day moving average is $301.06 and its two-hundred day moving average is $333.13. The company has a market cap of $14.70 billion, a PE ratio of 14.31, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 4,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $497,962.50. The trade was a 69.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,500 shares of company stock valued at $16,923,950 in the last 90 days. 10.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC boosted its stake in United Therapeutics by 30.4% in the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after purchasing an additional 2,702 shares in the last quarter. Korea Investment CORP lifted its position in United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after buying an additional 2,300 shares in the last quarter. Illumine Investment Management LLC acquired a new position in United Therapeutics during the 4th quarter worth about $3,015,000. ExodusPoint Capital Management LP acquired a new position in United Therapeutics during the 4th quarter worth about $1,899,000. Finally, Raymond James Financial Inc. acquired a new position in shares of United Therapeutics during the fourth quarter worth approximately $18,257,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.